



ERITREA PNEUMOCOCCAL VACCINE SUPPORT
This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Eritrea			
2. Grant Number: 1516-ERI-12c-X / 15-ERI-08c-Y			
3. Date of Decision Letter: 6 October 2014			
4. Date of the Partnership Framework Agreement: 16 April 2013			
5. Programme Title: NVS, Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID			
8. Programme Duration¹: 2015 - 2016			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2015	2016	Total ²
Programme Budget (US\$)	US\$969,000	US\$1,488,000	US\$2,457,000
10. Vaccine Introduction Grant: US\$100,000 payable up to six months before vaccine introduction.			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):³ The Annual Amount for 2015 has been amended.			
Type of supplies to be purchased with GAVI funds in each year		2015	
Number of Pneumococcal vaccines doses		176,400	
Number of AD syringes		197,900	
Number of safety boxes		2,200	
Annual Amounts (US\$)		US\$969,000	

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the amount that GAVI has approved.

12. Procurement agency: UNICEF.														
13. Self-procurement: Not applicable.														
<p>14. Co-financing obligations: Reference code: 1516-ERI-12c-X-C According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2015</th> <th>2016</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>10,800</td> <td>19,800</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$35,343</td> <td></td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$37,500</td> <td>US\$70,500</td> </tr> </tbody> </table>			Type of supplies to be purchased with Country funds in each year	2015	2016	Number of vaccine doses	10,800	19,800	Value of vaccine doses (US\$)	US\$35,343		Total Co-Financing Payments (US\$) (including freight)	US\$37,500	US\$70,500
Type of supplies to be purchased with Country funds in each year	2015	2016												
Number of vaccine doses	10,800	19,800												
Value of vaccine doses (US\$)	US\$35,343													
Total Co-Financing Payments (US\$) (including freight)	US\$37,500	US\$70,500												
15. Operational support for campaigns: Not applicable														
<table border="1"> <thead> <tr> <th></th> <th>2015</th> </tr> </thead> <tbody> <tr> <td>Grant amount (US\$)</td> <td>US\$</td> </tr> </tbody> </table>				2015	Grant amount (US\$)	US\$								
	2015													
Grant amount (US\$)	US\$													
16. Additional documents to be delivered for future disbursements:														
Reports, documents and other deliverables	Due dates													
Annual Progress Report or equivalent	As agreed with the Gavi Secretariat													
17. Financial Clarifications: Not applicable.														
18. Other conditions: Not applicable.														

On behalf of the GAVI Alliance



Hind Khatib-Othman
Managing Director, Country Programmes

6 October 2014